Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
10661studies shown
Showing 9,325-9,336 of 10,661
Drug study icon
CompletedNCT03185819

3 Fixed Doses of Intranasal Esketamine for depression

This study is completed in the United States, in France, in Belgium, .... It is testing 3 Fixed Doses of Intranasal Esketamine for depression.

In United States
Depression, SuicidalityDrugFrom 9 Years to 17 Years
Countries
United States, France, Belgium, ...
Sponsor
Janssen Research & Development, LLC
Condition
Depression, Suicidality
Drug study icon
CompletedNCT00772005

Armodafinil for schizophrenia

This study is completed in the United States. It is testing armodafinil for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Cephalon
Condition
Schizophrenia
Drug study icon
CompletedNCT01305408

Armodafinil Treatment (150 mg/Day) for depression

This study is completed in the United States, in Argentina, in Brazil, .... It is testing Armodafinil Treatment (150 mg/Day) for depression.

In United States
Bipolarity, DepressionDrugFrom 18 Years to 65 Years
Countries
United States, Argentina, Brazil, ...
Sponsor
Cephalon
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT01072630

Armodafinil Treatment for depression

This study is completed in the United States, in Australia, in France, .... It is testing armodafinil Treatment for depression.

In United States
Bipolarity, DepressionDrugFrom 18 Years to 65 Years
Countries
United States, Australia, France, ...
Sponsor
Cephalon
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT05401565

Balovaptan for PTSD

This study is completed in the United States. It is testing balovaptan for PTSD.

In United States
PTSDDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
Hoffmann-La Roche
Condition
PTSD
Drug study icon
CompletedNCT01009060

GSK239512 for schizophrenia

This study is completed in the United States. It is testing GSK239512 for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
GlaxoSmithKline
Condition
Schizophrenia
Drug study icon
CompletedNCT03160521

Risperidone for schizophrenia

This study is completed in the United States and in Ukraine. It is testing risperidone for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Ukraine
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
Drug study icon
CompletedNCT03870880

Risperidone ISM® for schizophrenia

This study is completed in the United States and in Ukraine. It is testing Risperidone ISM® for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Ukraine
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
Drug study icon
Active Not RecruitingNCT07221578

VQW-765 for anxiety

This study is active but not recruiting in the United States. It is testing VQW-765 for anxiety.

In United States
AnxietyDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanda Pharmaceuticals
Condition
Anxiety
Drug study icon
CompletedNCT03187769

Efficacy of ALKS 3831 on Body Weight for schizophrenia

This study is completed in the United States, in the United Kingdom, in Austria, .... It is testing Efficacy of ALKS 3831 on Body Weight for schizophrenia.

In United States
Bipolarity, SchizophreniaDrugFrom 16 Years to 40 Years
Countries
United States, United Kingdom, Austria, ...
Sponsor
Alkermes, Inc.
Condition
Bipolarity, Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.